Cancer patients offered support and information via Boots stores
Boots has teamed up with Macmillan Cancer Support to host drop-in cancer information sessions in over 100 stores this week for Cancertalk Week (15–22 February 2011).
During the sessions, specialists from Macmillan will be available to provide personalised information to people affected by cancer.
The sessions will form part of a wider approach to test how a partnership between MacMillan and Boots can best support people affected by cancer in their local communities. Macmillan aims to train 15,000 Boots pharmacists, dispensers and healthcare assistants on the issues surrounding cancer.
Karl Crane, director of pharmacy and retail at Boots UK, said: “Not everyone affected by cancer realises the extent of the support available from Macmillan Cancer Support. Through our partnership with Macmillan Cancer Support, we’re aiming to make people more aware of the ways we can help. We hope that through Cancertalk Week activities in-store, customers will feel able to talk about cancer and receive a valuable support service.”
Ciarán Devane, chief executive at Macmillan Cancer Support, added: “Cancer information and support makes a real difference to a patient’s quality of life. By bringing Cancertalk Week to the high street via Boots UK, we’re providing an easily accessible community resource to reach people who need it.”
In a YouGov online survey of 1,110 UK adults living with cancer, nearly a quarter (24 per cent) of people said they would feel comfortable talking about their cancer to a pharmacist and 31 per cent said they would find it helpful to receive information and support aboutcancer in a high street pharmacy.
The research also showed that 61 per cent of people living with cancer wanted information on the long-term impact of cancer treatment ontheir health, but less than a third (27 per cent) felt they received it. Almost half (49 per cent) of people wanted more information on how to cope with the emotional impact of their diagnosis or treatment, yet less than one in five (17 per cent) said they received it.
Citation: The Pharmaceutical Journal URI: 11068666
Recommended from Pharmaceutical Press